Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study by Patel, Deepen, MD, Couroux, Peter, MD, Hickey, Pascal, PhD, Salapatek, Anne Marie, PhD, Laidler, Paul, PhD, Larché, Mark, PhD, Hafner, Roderick P., PhD

Get full text

Safety of House Dust Mite Synthetic Peptide Immuno-Regulatory Epitopes in Patients with House Dust Mite Allergy and Controlled Asthma by Pawsey, Stephen, MD, Patel, Deepen, MD, Hafner, Rod, PhD, Hickey, Pascal L.C., PhD, Powell, John, MD

Get full text

The Nasal Allergen Challenge Protocol of the Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): Validation in a Clinical Trial of Cat Synthetic Peptide Immunoregulator... by Neighbour, Helen, Larché, Mark, PhD, Steacy, Lisa, BSc, Armstrong, Kristen, M.Sc, Hickey, Pascal L.C., PhD, Soliman, Mena, MBChB, Ellis, Anne, MD, MSc, FAAAAI

Get full text

Safety and Tolerability of Fel d 1-Derived Peptide Antigen Desensitization in Subjects with Controlled Asthma by Hickey, Pascal L.C., BPharm PhD, Cheema, Amarjit Singh, MD, Larche, Mark, PhD, Hafner, Rod, PhD

Get full text

Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD) by Larche, Mark, Hickey, Pascal, Hebert, Jacques, MD, Hafner, Rod, PhD

Get full text